None listed
Conditions
Interventions
Group 1 Type of group
For Children aged 2-11 years and adolescents aged 12-14 years weighing
Sponsors
PFIZER S.A.,
Eligibility
Age
2 Years to 17 Years
Inclusion criteria
Inclusion criteria: • Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Assent will be required (as applicable) for children per local regulations and for those who, in the investigator’s judgment, are able to comprehend. • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. • Immunocompromised state due to either: - Receipt of allogeneic hematopoetic stem cell transplantation after myeloablative or non-myeloablative conditioning; or - Hematologic malignancy (excluding subjects with progressive hematologic disease who have not responded or are not likely to respond to treatment). • Diagnosis of proven or probable or possible IA • Male or female from 2 to 17 years of age. • Female subjects of childbearing potential must have a negative pregnancy test PLUS adequate contraception as determined by the investigator for the duration of the trial.
Exclusion criteria
Exclusion criteria: • Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial. • History of allergy, hypersensitivity, or serious reaction to azole or echinocandin antifungals. • Female subjects who are pregnant or lactating. • Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis (ABPA). • Chronic IA with duration of symptoms or radiological findings for more than four weeks prior to study entry. • Receipt within 24 hours prior to randomization of any of the following medications: terfenadine, astemizole, cisapride, pimozide, or quinidine (because of the possibility of QT prolongation). • Concomitant receipt of any of the following medications: sirolimus, rifampin, rifabutin, carbamazepine, long-acting barbiturates (eg, Phenobarbital, mephobarbital), ritonavir, efavirenz, or ergot alkaloids (eg, ergotamine, dihydroergotamine). • Concomitant receipt of drugs with clinically relevant interactions with voriconazole unless closely monitored or dose adjusted. • Receipt of systemic antifungal treatment for the current episode of IA for a duration of greater than 96 hours; however, subjects receiving mold-active prophylaxis for greater than 96 hours may be enrolled provided that they meet criteria for proven or probable IA at the time of enrollment. • Severe liver dysfunction, defined as total bilirubin, AST, ALT, or alkaline phosphatase >5x upper limit of normal. • Moderate or severe renal impairment, with calculated creatinine clearance <50 mL/min. • Mechanical ventilation at the time of enrollment. • Previously randomized into this trial. • Not expected to survive for at least five days due to the current episode of IA. • High likelihood of death due to factors unrelated to aspergillosis (eg, due to relapsed malignancy, severe graft versus host disease, other underlying diseases, etc.) within 30 days following planned enrollment, at the investigator’s discretion. • Participation in a study of an investigational drug or device (without any FDA or EMEA approved indications) within four weeks of study entry. The investigational use of licensed agents is permitted if the subject is on a stable regimen for four weeks prior to study start and expected to remain on the stable regimen for the duration of the trial. • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study. • Concomitant administration of systemic agents active against Aspergillus species is not permissible during the study treatment period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Determined by the rates of adverse events. The set of subjects for these evaluations will be the safety population, defined as all subjects who received at least one dose of the drug under study. The sponsor has standard algorithms to report adverse events, which will be used in the analysis of the data in this trial. Measure:Safety and tolerability of Voriconazole and Anidulafungin in combination versus Voriconazole alone Timepoints:During the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Success: a subject that achieves a complete or partial global response will be categorized as a successful response. Failure: a subject will be categorized as an unsuccessful response, if the overall response is Stable, Fail or undetermined Measure:The overall response Timepoints:will be evaluated at 6 weeks and in the FDT ; Outcome name:They will be determined, together with the differences in treatment and the corresponding confidence intervals. The moment of death is summarized in the non-parametric production of Kaplan Meier that estimates the survival function and the plotting of the estimates as a function of time. The causes of death will be presented. All summaries and mortality analysis will be presented by the MITT and safety populations. Measure:All types of causes of mortality at 6 weeks and in the EOT Timepoints:at 6 weeks and in the EOT ; Outcome name:If the subjects cannot finish the visit of week 6, they will be contacted (phone, mail or email) to determine the condition of survival in week 6. If a subject cannot be contacted, the status of survival will be You can get it through a family member, hospital or clinic record or information that is in the public domain. Measure:Survival Evaluation Timepoints:Week 6 ; Outcome name:1. Complete response: Resolution of all clinical signs and symptoms; 2. Partial response: significant improvement of clinical signs and symptoms; 3- Stable: No changes from baseline in clinical signs and symptoms; 4. Failure: The worsening of clinical signs and symptoms compared to baseline; 5. Indeterminate Response: If information is missing or unavailable to determine the clinical response to treatment. Measure:Determination of the Clinical Response Timepoints:During treatment | — |
Countries
Belgium, Czech Republic, Denmark, France, Germany, Netherlands, Peru, Poland, United Kindgdom
Contacts
Public ContactSergio Luis Reyes
PFIZER S.A.
Outcome results
None listed